<DOC>
	<DOCNO>NCT02369536</DOCNO>
	<brief_summary>The objective study provide clinical data support effectiveness mixture ingredients natural origin , suitably select package , protection liver damage , subject NAFLD . Study design : double-blind , randomize , multicentre trial , placebo-controlled two parallel group . The study participant healthy volunteer , since liver-related clinical symptom , simply laboratory ( plasma level great normal least one liver parameter -aspartate aminotransferase AST , alanine aminotransferase ALT γ -glutamyltranspeptidase γ-GT ) instrumental ( ultrasonographic abnormality steatosic liver ) test alter compare normal range . Three month treatment nutraceutical mixture placebo . Outcomes tested end treatment - 3 month ) .</brief_summary>
	<brief_title>Efficacy Natural Components Mixture Treatment Non Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description>A correct hepatic function highly relevant epidemiological point view . In Italy , Non Alcoholic Fatty Liver Disease - NAFLD - prevalence 20-25 % adult population , peak 50-70 % within obese type-2 diabetes population : frequent cause hematic change cytonecrosis enzymes , explain 90 % asymptomatic high level transaminase . NAFLD natural history associate increase cerebro cardiovascular risk , healthy subject diabetic patient . Its prevention treatment great interest , particular dietary nutraceutical intervention object innovative research . It also know 65 % subject hepatic dysfunction consume plant extract , like silymarin Cardo marianum . A recent trial show improvement hepatic function subject NAFLD treat silybin , combine phosphatidylcholine vitamin E. These finding provide valuable information new therapeutic strategy , warrant investigation . For natural substance health claim relate liver function fact approve European Food Safety Authority ( EFSA ) . The exception constitute food source choline , maintenance normal hepatic function claim . The objective study provide clinical data support effectiveness mixture ingredients natural origin , suitably select package , protection liver damage , subject NAFLD . Treatment : subject randomize receive nutraceutical formulation placebo three month , amount two capsule ( 800 mg ) day , one time . All subject , sign write informed consent participation study , receive appropriate recomendations diet physical exercise . A clinic visit , collection patient clinical pharmacological history record adverse event , liver ultrasound , measurement weight height calculation BMI , measure arterial blood pressure , collection sample venous blood , fast condition , hematochemical test , make baseline ( T0 ) ; examination test ( except liver ultrasound ) repeat three month treatment ( T1 ) . Primary end-points study : hematic level hepatic enzyme : ALT , AST γ-GT . Secondary end-points study : 1 . Hepatic function : direct indirect bilirubin ; 2 . Inflammation marker : C Reactive Protein ( CRP ) , interleukin ( IL ) -6 , IL-1β , IL-8 , IL-10 , Receptor Advanced Glycation End Products ( RAGE ) , Advanced Glycation End Products ( AGE ) , insulin-like growth factor-1 ( IGF-1 ) 3 . Haemostatic function : Factor VII , fibrinogen , thrombin generation without thrombomodulin , antithrombin ( AT ) , tissue-type Plasminogen Activator ( t-PA ) , Plasminogen Activator Inhibitor-1 ( PAI-1 ) , thrombin activatable fibrinolysis inhibitor ( TAFI ) activate TAFI ( TAFIa ) , plasmin-antiplasmin complex , plasma fibrinolytic capacity ; 4 . Metabolic syndrome parameter : glycemia , triglyceride , HDL cholesterol , insulin e insulin-resistance ( HOMA-IR homeostasis model assessment-estimated insulin resistance ) , adiponectin ; 5 . Apoptosis parameter : total cytokeratin-18 ( M65 antigene ) , M30 M65/M65ED , soluble fa soluble fas ligand . A weekly food diary administer subject end treatment , highlight possible change dietary habit study . In addition , subject NAFLD Fibrosis Score ( NFS ) , composite score prognostic value conversion NAFDL fibrotic hepatitis disease severity , calculate . This score include age , body mass index , platelet count , albumin , relationship AST ALT , presence diabetes . A sub-analysis do evaluate efficacy treatment synergistic blend ingredient subject high , compare low NFS . Sample size calculation : Establishing Alpha = 0.05 Β = 80 % , number 150 people ( 75 per treatment arm ) evaluate difference two group ( T1 T0 ) equal 46 % standard deviation mean two liver function parameter select ( primary end-points ) , particular , difference 11.5 ALT ( 17 % average ) , 7.1 AST ( 17 % average ) 13.8 γ-GT ( 19 % average ) . This calculation also include drop-out 10 % sample enrol study . Compliance treatment monitor counting capsule return box end treatment .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>subject non alcoholic fatty liver disease ( NAFLD ) present ultrasonographic abnormality steatosic liver ( hyperechogenic parenchyma ) plasma level great normal ( range recruit center ) least one follow parameter ( aspartate aminotransferase AST , alanine aminotransferase ALT , γ glutamyltranspeptidase γGT ) . history alcohol abuse use drug associate development hepatic steatosis malnutrition alcoholic chronic liver disease chronic liver disease different etiology ( autoimmune disease , primary biliary cirrhosis , primary sclerosing cholangitis , hereditary hemochromatosis , Wilson 's disease , deficits alpha1 antitrypsin , celiac disease ) severe renal , cardiac respiratory insufficiency malignant tumor intolerance component active ingredient formulation woman pregnant planned pregnancy within three month woman breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>NAFLD</keyword>
	<keyword>nutraceutical mixture</keyword>
</DOC>